GlassScriptPhysician profile
Anupama Matcha
NPI 1033341565
$2,636.37
in general payments reported to CMS, 2019-2025
19 companies · $465 in 2025
The $465 reported for 2025 was more than what 89% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $125 · 2022: $543 · 2023: $649 · 2024: $616 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,730.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $720.57 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $372.48 | 2019-2025 | Zerbaxa, Verquvo, Dificid |
| Novartis Pharmaceuticals Corporation | $324.93 | 2022-2025 | |
| Abbvie INC. | $302.54 | 2022-2025 | |
| Allergan, INC. | $256.03 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.34 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.04 | 2022-2023 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Novo Nordisk INC | $70.06 | 2023-2024 | Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $61.25 | 2022-2025 | Eliquis |
| Janssen Pharmaceuticals, INC | $54.19 | 2022-2024 | Xarelto |
| Paratek Pharmaceuticals, INC. | $49.32 | 2022-2023 | Nuzyra |
| Gilead Sciences, INC. | $31.72 | 2024 | |
| Electromed, INC. | $29.97 | 2023 | Smartvest |
| Cvrx, INC. | $29.72 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $28.94 | 2022-2024 | Farxiga |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $26.26 | 2022 | |
| Philips North America LLC | $21.01 | 2023 | |
| Smith+Nephew, INC. | $19.44 | 2025 | Collagenase Santyl |
| Alexion Pharmaceuticals, INC. | $15.56 | 2024 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anupama Matcha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.